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Abstract
Aims/hypothesis The aim of this work was to determine how weight patterns together with blood glucose, BP and lipids vary at
diagnosis of diabetes by age, sex and ethnicity.
Methods Using the UKClinical Practice Research Datalink, we identified people with type 2 diabetes (n = 187,601) diagnosed in
1998–2015 and compared their weights, HbA1c, BP and lipid levels at diagnosis with age-matched people without diabetes (n =
906,182), by sex and ethnic group.
Results Younger age at diagnosis was associated with greater adjustedmean difference (95%CI) in weight between those with vs
without type 2 diabetes: 18.7 (18.3, 19.1) kg at age 20–39 years and 5.3 (5.0, 5.5) kg at age ≥ 80 years. Weight differentials were
maximal in white women, and were around double in white people compared with South Asian and black people. Despite lower
absolute values, BP differences were also greater at younger age of diabetes onset: 7 (6, 7) mmHg at age 20–39 years vs −0.5
(−0.9, −0.2) at age ≥ 80 years. BP differences were greatest in white people, and especially in women. Triacylglycerol level
differences were greatest in younger men. Finally, HbA1c levels were also higher with younger onset diabetes, particularly in
black people.
Conclusions/interpretation At diagnosis of type 2 diabetes, when compared with people without diabetes, weight and BP
differentials were greater in younger vs older people, in women vs men and in white vs South Asian and black people. These
differences were observed even though South Asian and black people tend to develop diabetes a decade earlier with either similar
or greater dysglycaemia. These striking patterns may have implications for management and prevention.
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Introduction
Recent studies show that diagnosis of type 2 diabetes at youn-
ger ages is associated with greater excess CVD risk than when
the diagnosis occurs later in life [1, 2]. Diagnosis of type 2
diabetes before the age of 40 years is associated with a 10 year
reduction in life expectancy, on average, compared with age-
matched people without diabetes. However, this excess risk
gradually attenuates when diabetes is diagnosed at older ages,
such that there is a negligible effect on life expectancy when
diagnosis occurs after 80 years of age [3–5]. There are also
historical data suggesting that excess risk of cardiovascular
events and all-cause mortality from type 2 diabetes is greater
in women than in men [6–9]. We also recently observed that
for a given age of diagnosis the number of life-years lost due
to type 2 diabetes was lower in South Asian and black people
compared with white Europeans [5]. This is somewhat
surprising and may reflect earlier CVD risk factor
management in people from minority ethnic groups as they
tend to develop diabetes earlier than white people, or it may
reflect other poorly understood factors.
There is a paucity of data on characteristics of individuals
at the time of diagnosis of diabetes and how this might have
changed over time. Some data indicate that clinical character-
istics at the time of developing type 2 diabetes vary by age, sex
and ethnicity [10–17]. One such variable is BMI, with studies
reporting that it is much higher at diabetes diagnosis in youn-
ger vs older people, in women vs men, and in people of white
European descent vs other ethnicities [15–17]. There are also
some data suggesting more adverse lipid profiles and higher
BP levels in people who develop diabetes at younger ages vs
non-diabetic age- and sex-matched adults, and in women vs
men [10–13]. The majority of these studies were limited in
their generalisability due to the data source or specific popu-
lations considered and they did not include ethnically diverse
populations or only observed risk factor levels in people with
diabetes.
We hypothesise that at the time of type 2 diabetes diagno-
sis, CVD risk factors would be higher when compared with
those in people without diabetes and that these differences
would vary meaningfully by age, sex and ethnicity. We aimed
to determine whether differences in risk factors could better
explain contrasting risks for developing type 2 diabetes and its
Diabetologia
complications. These data are important because they may
help focus where more aggressive care is needed to prevent
and manage type 2 diabetes.
Methods
Data sourceWe used data from the Clinical Practice Research
Datalink (CPRD), an anonymised, longitudinal primary care
medical record database from participating UK general prac-
tices [18]. Individuals included in the CPRD are broadly
representative of the general population in terms of age, sex
and ethnicity [18]. The CPRD dataset was linked, at patient-
level, to hospitalisation data (Hospital Episode Statistics
[HES]), national mortality data (Office for National Statistics
[ONS]) and deprivation data (Index of Multiple Deprivation
[IMD] 2010) for all eligible patients in 383 linkage-consenting
English general practices.
Study population We identified a cohort of individuals with
incident diabetes (N = 193,952), from Read codes (https://
digital.nhs.uk/article/1104/Read-Codes) in the electronic
health record; the cohort included those for whom the first
diagnostic code for diabetes (type 1 or type 2 diabetes) was
recorded between 1 January 1998 and 31March 2015, with no
diagnoses prior to this date. The index date was taken as the
date of the first diabetes diagnostic Read code.
The cohort of individuals identified with incident diabetes
were initially assigned to ‘definite’, ‘probable’ and ‘possible’
type 1 diabetes or type 2 diabetes groups. Due to the nature of
primary care data and recording, misclassification, misdiagno-
sis and miscoding can occur [19]. To try and mitigate these
errors, we used a validated algorithm for use in routinely
collected data that re-classifies type 1 and type 2 diabetes
based on diagnostic codes, glucose-lowering drugs, age,
BMI and ethnicity [20]. The implementation of the algorithm
(including detailed patient numbers for each step) in this
population has been described previously [5]. Only those with
a final classification of type 2 diabetes (N = 187,968) were
considered (type 1 diabetes N = 5984). Additionally, people
aged less than 20 years at the index date were excluded,
resulting in a final type 2 diabetes cohort of 187,601.
Individuals with type 2 diabetes were matched with up to
five control individuals without diabetes who were currently
registered and contributing data at the cases’ index date, by
year of birth (±2 years), sex, general practice and index date.
All individuals were observed from the index date to study
end (31March 2015), practice’s last data collection date, death
or transfer out of practice, whichever occurred earliest.
Cohort demographics and baseline characteristics Age, as
defined at the index date, was categorised into six groups:
20–39 years; 40–49 years; 50–59 years; 60–69 years; 70–
79 years; and ≥ 80 years. Ethnicity was identified from prima-
ry care records and through linkage with HES; the classifica-
tion of ethnicity using the two data sources has been described
previously and further details are provided in electronic
supplementary materials (ESM) Methods and ESM Fig. 1
[5]. Ethnicity was categorised into five groups: white, South
Asian, black/black British, other and unknown. Deprivation
data was defined using the IMD 2010, a national scheme
based on seven deprivation domains and available at small-
area level to link with the address of the patient, categorised
into five quintiles: IMD 1 (least deprived) to IMD 5 (most
deprived) [21]. Drug prescriptions (issue of prescription) at
baseline were defined as a prescription within 90 days before
or after the index date. Cardiovascular disease (myocardial
infarction, stroke, CHD, peripheral vascular disease, angina
pectoris) and renal disease (chronic kidney disease stage 4
and above) were defined by Read code, up to the index date.
Outcome measures Body weight, BMI, systolic BP and lipid
levels (total cholesterol, HDL-cholesterol, non-HDL-choles-
terol, triacylglycerol) were defined as the closest measure up
to 12months before and after the index date (this time window
was used to improve capture of available data, particularly for
people without diabetes). HbA1c was only examined in people
with type 2 diabetes due to the proportion of missing data in
those without diabetes.
Statistical analysis Descriptive characteristics for people with
type 2 diabetes andmatched individuals without diabetes were
summarised using mean (±SD) and proportions as
appropriate.
A multivariate imputation by chained equations (MICE)
algorithm was used to impute missing data on baseline vari-
ables (BMI, weight, BP, cholesterol, triacylglycerol). Details
on the proportion of missingness and differences in character-
istics between those with and without missing data are provid-
ed in the ESM Tables 1–4 and ESM Key differences in
missingness. Imputation models were estimated separately
for people with type 2 diabetes and control-group individuals
without diabetes within age, age–sex and age–ethnicity strata.
See ESM Imputation model for a list of variables included in
the imputation model. Five imputed datasets were generated.
Analyses comparing biological outcome measures
between the type 2 diabetes and control groups were strat-
ified by age, age–sex and age–ethnicity. Multiple linear
regression, adjusting for deprivation and accounting for
matching, was used to calculate the adjusted mean differ-
ences (95% CI) in biological variables between those with
and without type 2 diabetes across age groups. Estimates
were combined across the five datasets using Rubin’s
rules [22]. p< 0.05 was considered statistically significant.
All statistical analyses were performed using Stata 15.1
(StataCorp, USA).
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Table 1 Baseline characteristics of people with incident type 2 diabetes
Characteristic All Sex Ethnicity
Male Female White South Asian Black
N 187,601 103,607 83,994 143,481 9486 4451
Men, n (%) 103,607 (55.2) 78,573 (54.8) 5142 (54.2) 2204 (49.5)
Age, years 61.9 ± 14.1 60.4 ± 13.4 63.7 ± 14.8 63.3 ± 13.8 52.6 ± 13.5 54.0 ± 13.8
Age group, n (%)
20–39 years 11,997 (6.4) 6779 (6.5) 5218 (6.2) 7170 (5.0) 1737 (18.3) 650 (14.6)
40–49 years 25,770 (13.7) 15,949 (15.4) 9821 (11.7) 16,956 (11.8) 2310 (24.4) 1179 (26.5)
50–59 years 41,491 (22.1) 25,186 (24.3) 16,305 (19.4) 30,162 (21.0) 2464 (26.0) 1075 (24.2)
60–69 years 48,469 (25.8) 27,917 (27.0) 20,552 (24.5) 38,539 (26.9) 1837 (19.4) 868 (19.5)
70–79 years 39,452 (21.0) 19,876 (19.2) 19,576 (23.3) 33,198 (23.1) 934 (9.9) 528 (11.9)
≥ 80 years 20,422 (10.9) 7900 (7.6) 12,552 (14.9) 17,456 (12.2) 204 (2.2) 151 (3.4)
Ethnicity, n (%)
White 143,481 (76.5) 78,573 (75.8) 64,908 (77.3)
South Asian 9486 (5.1) 5142 (5.0) 4344 (5.2)
Black 4451 (2.4) 2204 (2.1) 2247 (2.7)
Other 2480 (1.3) 1366 (1.3) 1114 (1.3)
Unknown 27,703 (14.8) 16,322 (15.8) 11,381 (13.6)
Deprivation (IMD 2010), n (%)
IMD 1 (least) 34,290 (18.3) 19,750 (19.1) 14,540 (17.3) 26,192 (18.3) 1238 (13.1) 222 (5.0)
IMD 2 40,934 (21.8) 23,177 (22.4) 17,757 (21.1) 32,691 (22.8) 1405 (14.8) 365 (8.2)
IMD 3 38,5337 (20.5) 21,443 (20.7) 17,094 (20.4) 29,504 (20.6) 1963 (20.7) 713 (16.0)
IMD 4 39,128 (20.9) 21,121 (20.4) 18,007 (21.4) 29,432 (20.5) 2300 (24.3) 1440 (32.4)
IMD 5 (most) 34,379 (18.3) 17,956 (17.3) 16,423 (19.6) 25,420 (17.7) 2566 (27.1) 1703 (38.3)
Unknown 333 (0.2) 160 (0.2) 173 (0.2) 242 (0.2) 14 (0.2) 8 (0.2)
CVD, n (%)a 37,765 (20.1) 23,453 (22.6) 14,312 (17.0) 32,255 (22.5) 1191 (12.6) 359 (8.1)
Renal disease (CKD stage ≥4), n (%) 2335 (1.2) 1257 (1.2) 1078 (1.3) 1943 (1.4) 109 (1.2) 55 (1.2)
Biological variables (±12 months from diagnosis)
BMI, kg/m2 31.3 ± 6.9 31.1 ± 6.2 31.6 ± 7.6 31.6 ± 6.9 28.5 ± 5.8 31.1 ± 6.6
Missing, % 18.6 17.7 19.6 17.9 23.3 24.0
Weight, kg 88.9 ± 21.1 94.0 ± 19.9 82.4 ± 20.6 89.9 ± 21.2 77.4 ± 16.3 87.7 ± 19.0
Missing, % 17.0 16.2 17.9 16.4 21.4 22.4
Total cholesterol, mmol/l 5.2 ± 1.3 5.0 ± 1.3 5.3 ± 1.3 5.2 ± 1.3 5.1 ± 1.2 5.1 ± 1.2
Missing, % 16.8 15.9 18.0 16.2 20.6 22.4
HDL-cholesterol, mmol/l 1.2 ± 0.4 1.1 ± 0.3 1.3 ± 0.4 1.2 ± 0.4 1.2 ± 0.3 1.3 ± 0.4
Missing, % 28.9 28.1 29.9 28.6 28.8 30.6
Non-HDL-cholesterol, mmol/l 4.0 ± 1.3 3.9 ± 1.3 4.0 ± 1.3 3.9 ± 1.3 3.9 ± 1.2 3.8 ± 1.2
Missing, % 29.0 28.2 29.9 28.6 28.9 30.6
Triacylglycerol, mmol/l 2.6 ± 2.6 2.5 ± 3.0 2.1 ± 1.9 2.3 ± 2.5 2.3 ± 3.4 1.5 ± 1.5
Missing, % 29.9 28.8 31.3 29.9 28.4 29.3
BP
Systolic, mmHg 140 ± 19 139 ± 18 140 ± 20 140 ± 19 133 ± 18 138 ± 19
Diastolic, mmHg 81 ± 11 81 ± 11 80 ± 11 81 ± 11 81 ± 11 82 ± 11
Missing, % 12.5 12.4 12.7 11.9 18.1 18.3
HbA1c
mmol/mol 62 ± 22 63 ± 23 61 ± 21 61 ± 22 65 ± 22 68 ± 27
% 7.8 ± 2.0 7.9 ± 2.1 7.7 ± 2.0 7.8 ± 2.0 8.1 ± 2.0 8.4 ± 2.4
Missing (%) 16.7 16.5 17.0 16.1 21.4 22.9
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Results
Baseline characteristics of people with type 2 diabetes are
presented in Table 1 and those of control groups without
diabetes are presented in ESM Table 5. The cohort comprised
187,601 people with incident type 2 diabetes (mean ± SD age
61.9 ± 14.1 years; 55.2%male sex; 76.5% white) and 906,182
individuals without diabetes as matched controls. People with
type 2 diabetes were more likely than control individuals to be
obese, to have high BP and to be prescribed antihypertensive,
lipid-lowering and antiplatelet agents. At diagnosis of type 2
diabetes, women were on average 3 years older thanmen (Fig.
1a) and had higher mean BMI and cholesterol and lower
HbA1c. Women were less likely than men to receive lipid-
lowering and antiplatelet medication but were more likely to
receive antihypertensive agents (Table 1).
Compared with white people, South Asian and black
people were on average ~ 9–10 years younger at the onset of
type 2 diabetes and had a higher level of deprivation (Table 1,
Fig. 1b). Black people and particularly South Asian people
developed type 2 diabetes at a substantially lower mean
weight/BMI than white people and had lower systolic BP
levels but higher HbA1c, on average. Correspondingly,
compared with white people, a higher percentage of
South Asian and black people received prescriptions for
glucose-lowering medications and lower proportions were
prescribed lipid-lowering, antihypertensive and antiplatelet
medications.
Biological variables at age of type 2 diabetes onset were
compared against those for control individuals at the same age
without diabetes (ESM Table 6). Younger age at type 2 diabe-
tes diagnosis was associated with higher mean body weight in
individuals with diabetes and a greater differential compared
with individuals without diabetes. As an illustration, in people
aged 20–39 years, the mean ± SD weight was 99.7 ± 27.3 kg
for those with type 2 diabetes and 81.0 ± 22.5 kg for those
without diabetes (adjusted mean [95% CI] difference 18.7
[18.3, 19.1] kg). However, in people aged ≥80 years, the
mean ± SD weight was 72.1 ± 17.0 kg in those with type 2
diabetes and 66.9 ± 18.5 kg for those without diabetes (adjust-
ed mean [95% CI] difference 5.3 [5.0, 5.5] kg). A similar age-
related pattern was observed for BMI, systolic BP and triac-
ylglycerol. With the exception of systolic BP levels, higher
mean levels of risk factors were observed for people in whom
type 2 diabetes was diagnosed at a younger vs older age.
Larger differences between those with and without type 2
diabetes were consistently observed in younger age groups,
with a narrowing in risk factor levels in older age groups.
Whilst this was the case for systolic blood pressure, with the
largest difference at ages 20–39 (adjusted mean difference 6
[6, 7] mmHg), in those aged ≥80 years, blood pressure values
in those with type 2 diabetes exceeded those in individuals
Table 1 (continued)
Characteristic All Sex Ethnicity
Male Female White South Asian Black
Drug prescriptions, %
Diabetes medication
Any oral hypoglycaemic 44.1 44.7 43.4 43.3 47.6 51.6
Metformin 34.6 35.1 33.9 33.7 39.2 40.9
Sulfonylurea 11.0 11.3 10.7 10.7 11.9 13.4
Insulin 3.6 3.6 3.6 3.6 3.2 6.2
Other 1.6 1.6 1.7 1.6 2.2 2.0
Antihypertensive agent
Any 54.9 53.0 57.2 57.8 36.5 42.8
α-Blocker 4.3 4.5 4.0 4.6 2.3 5.1
Angiotensin-2 receptor blocker 8.7 7.7 9.9 9.1 8.0 7.5
ACE inhibitor 29.4 31.2 27.2 30.9 19.5 20.5
β-Blocker 19.4 19.5 19.2 21.0 11.1 10.2
Calcium-channel blocker 20.6 20.5 20.7 21.2 14.4 26.5
Diuretic (thiazide, potassium-sparing or loop) 27.5 22.2 34.0 29.8 11.8 19.6
Lipid-lowering therapy (any) 44.1 46.0 41.8 46.0 37.1 30.6
Antiplatelets (any) 26.0 27.6 23.9 28.1 18.5 15.2
Data are mean ± SD, n (%) or %, where indicated
a CVD includes myocardial infarction, stroke, CHD, peripheral vascular disease and angina pectoris
CKD, chronic kidney disease
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without diabetes (adjusted mean difference −0.5 [−0.9, −0.2]
mmHg).
This relationship between age and biological variables
was observed across sexes. BMI, weight, systolic BP and
triacylglycerol differences between those with and with-
out type 2 diabetes were substantially greater in women
than in men, particularly at younger ages (Fig. 2a–d and
ESM Table 7). For weight, the adjusted mean difference
(95% CI) in women aged 20–39 years was 23.1 (22.5,
23.7) kg, reducing to 5.3 (5.0, 5.6) kg in women aged
≥80 years. In men, the adjusted mean difference at age
20–39 years was 15.2 (14.6, 15.7) kg and 4.9 (4.5, 5.3) kg
at age ≥ 80 years.
Across age groups, there were marked ethnic differences in
weight, BMI, BP and lipid levels (ESM Table 8). White
people with type 2 diabetes were more likely to have higher
levels for these risk factors at diagnosis than South Asian and
black people. The differences between those with and without
type 2 diabetes was greatest in white people, except for systol-
ic blood pressure where this was lost in those aged ≥50 years
(Fig. 3a–d and ESM Table 8). With the exception of people
aged ≥80 years, across all age bands, the mean weight differ-
ence (95% CI) between people age 20–39 years with type 2
diabetes and control individuals of white ethnicity was
approximately double that observed in South Asian and black
people: 24.3 (23.8, 24.9) kg in white people; 11.1 (9.8, 12.3)
kg in South Asian people; and 14.2 (11.9, 16.4) kg in black
people. Similarly, for BMI at age 20–39 years, the mean
difference (95% CI) was 8.4 (8.2, 8.5) kg/m2 in white people,
4.1 (3.7, 4.5) kg/m2 in South Asian people and 4.9 (4.1, 5.8)
kg/m2 in black people. For systolic BP and triacylglycerol, the
differential between those with and without diabetes was
greater in white people than in the other two ethnic groups
only up to the ages of 49 years and 69 years, respectively.
While we only examined HbA1c in those with new-onset
diabetes, these data showed markedly higher mean HbA1c at
younger ages, more so in men than in women and in black
people compared with the two other ethnicities across nearly
all age groups (Figs. 2e, 3e).
The same patterns were observed across ethnic–sex
subgroups (ESM Table 9). The impact of diabetes on
BMI, weight and systolic BP was most substantial in white
women at any given age compared with South Asian and
black men and women and was particularly prominent in
younger white women. At age 20–39 years, the mean (95%
CI) difference in weight between individuals with and
without type 2 diabetes was 27.6 (26.9, 28.3) kg in white
women, 13.1 (11.4, 14.7) kg in South Asian women, 16.6
(14.2, 19.0) kg in black women, 20.2 (19.5, 20.9) kg in
white men, 7.6 (5.7, 9.4) kg in South Asian men and 11.1
(7.6, 14.7) kg in black men. Similarly, at age 20–39 years,
the mean (95% CI) difference in systolic BP between those
with and without type 2 diabetes was 9.7 (9.0, 10.3) mmHg
in white women, 7.6 (5.7, 9.5) mmHg in South Asian
women, 6.8 (4.0, 9.6) mmHg in black women, 7.6 (6.9,
8.3) mmHg in white men, 5.2 (3.7, 6.7) mmHg in South
Asian men and 6.1 (3.6, 8.6) mmHg in black men.
Discussion
In this large contemporary primary care-based study from
England, our findings were as follows: (1) there was an asso-
ciation between younger age at type 2 diabetes diagnosis and a
higher number of elevated cardiovascular risk factors; (2) the
differences in weight, BMI and systolic BP in individuals with
vs without type 2 diabetes were more marked in women than
in men, especially at younger ages, whereas HbA1c and triac-
ylglycerol tended to be higher in men; (3) white people with
type 2 diabetes were more likely to have higher weight, BMI,
BP and triacylglycerol levels across all age groups (except for
the very oldest groups) than South Asian and black people
with type 2 diabetes. This poorer cardiovascular risk factor
profile may help explain previous observations that young
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Fig. 1 Age distribution at diagnosis of type 2 diabetes by sex (a) and ethnicity (b)
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people diagnosed with type 2 diabetes, across all ethnicities,
lose more life-years from diabetes than those diagnosed when
older [5]. It also explains why, in historical studies, women
had greater increase in their relative risk for CVD than men
when they develop diabetes, with high BP being a stronger
risk factor for CVD than raised triacylglycerol [5, 23]. These
data also might explain our prior finding which linked greater
loss of life-years from type 2 diabetes in white vs South Asian
and black people [5].
Regarding sex differences, it has been established that
women generally have a higher BMI than men when diag-
nosed with type 2 diabetes [14, 24, 25]. In both men and
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women, the BMI differences are most marked at younger ages
of diagnosis and the differences narrowwith diagnosis at older
ages. A younger age of onset of obesity leads to a greater
cumulative exposure to obesity, which may contribute to a
younger age of onset of diabetes [15, 26]. Older people being
diagnosed with diabetes at a lower body weight could in part
be explained by them having a lower cumulative lifetime
exposure to obesity.
Young women appear to undergo larger excess weight gain
than men prior to being diagnosed with type 2 diabetes [24,
25]. It has been suggested that women may experience greater
adverse metabolic changes than men as they develop diabetes,
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Fig. 3 Adjusted age-specific mean (95% CI) differences in BMI (a),
weight (b), systolic BP (c) and triacylglycerol level (d) in white, South
Asian and black people recently diagnosed with type 2 diabetes compared
with people without diabetes. (e) Age-specific mean HbA1c levels in
white, South Asian and black people recently diagnosed with type 2
diabetes ≥ m2
Diabetologia
with a poorer cardiovascular risk factor profile when
compared with their non-diabetic counterparts. However,
while this has been well documented for BMI, weight differ-
ences have not been reported and less is known about the
impact on other risk factors, especially across the age spec-
trum. In our comprehensive comparison of seven cardiovas-
cular risk markers, we identified bigger differences (compared
with their non-diabetic counterparts) in weight, systolic BP
and HDL-cholesterol in women than in men at the diagnosis
of type 2 diabetes at any age but particularly in younger
people. The converse was seen with triacylglycerol, with
men showing a trend for higher levels at the onset of type 2
diabetes, most notably in the youngest age groups.
Understanding these patterns, particularly the sex differences,
are important considerations for future cardiovascular risk
evaluation. Finally, sex biases in prescribing of medications
to manage cardiovascular risk factors in people with diabetes
have been identified: women are less likely to be prescribed
medications for adverse risk factors and/or established CVD
[27–30]. Therefore, greater awareness of sex- and age-related
differences in biological factors should prompt appropriate
intervention.
Regarding ethnic differences, the South Asian and black
people with type 2 diabetes were on average 9–10 years youn-
ger than the white population. This may arise from the higher
diabetes incidence rates seen in younger age groups or may
reflect the age distribution of the different ethnic groups.
South Asian and black people were observed to present with
a different cardiometabolic risk profile, with typically higher
HbA1c, lower BMI, and established micro- and macrovascular
complications [14, 31–33]. As identified previously by Paul
et al. [14], and shown in this cohort, white people with type 2
diabetes had a pattern of presenting with higher BMI at any age
compared with South Asian and black people, with larger
ethnic differences in BMI levels reported at younger ages. We
extend these findings by observing a similar pattern across other
risk factors including weight, systolic BP and triacylglycerol in
white people, as well as a tendency towards higher HbA1c
levels in black people. Furthermore, greater risk factor burden
at diagnosis was seen in white people, suggesting that they may
undergo a greater deterioration in cardiometabolic risk factors
on their pathway to developing diabetes. In particular, white
women with type 2 diabetes had the most substantial burden
of CVD risk factors when compared with their non-diabetic
white counterparts. These findings may, in part, help to explain
mechanisms behind findings from our previous research on this
cohort wherein white people and particularly white women
with type 2 diabetes had a greater likelihood for poorer life
expectancy and a greater risk of CVD than South Asian and
black women [5]. Earlier treatment of abnormal cardiometabol-
ic risk factors in South Asian and black people may also play a
role, given their development of disease at a younger age. As
South Asian people are known to have an elevated risk of CVD
compared with white Europeans [34], there has been a greater
emphasis in these populations, particularly for those with type 2
diabetes, to reduce modifiable risk factors through lifestyle
changes and drug management for primary and secondary
CVD prevention [35].
This study has several important strengths: (1) we obtained
a large cohort of people with type 2 diabetes identified from
primary care, reducing the likelihood of significant selection
bias; (2) we applied a validated algorithm to identify type 2
diabetes to mitigate any potential miscoding or misclassifica-
tion from electronic health records; (3) we had clinical and
prescribing information on people with and without type 2
diabetes; and (4) we combined data from general practice
and hospital records to increase completeness and accuracy
of ethnicity information.
Our study has several potential limitations. First, there is
the potential for misclassification of diabetes when using
routinely collected primary care data without validation from
consultation free text. The accuracy of primary care Read
codes depends on the team entering them, the clinicians’ time
and information-technology skills, certainty of diagnosis and
organisational issues [36]. The algorithm proposed and vali-
dated by de Lusignan et al. [20] uses additional information
beyond Read codes alone. These clinical features have been
identified by The Royal College of General Practitioners and
others, as being important for differentiating between type 1
and type 2 diabetes [19, 37]; therefore, after applying the
algorithm to our cohort, we would expect the prevalence of
misclassification of the final diabetes type to be lower than the
initial classification. However, any residual misclassification
might bias our results towards the null, so our results are likely
to be conservative estimates of the true difference between
control individuals and people diagnosed with type 2 diabetes.
Second, depending on the characteristics of an individual, the
assessment of type 2 diabetes prompted by a clinician may
represent either screening or diagnostic testing [38, 39]. These
are two distinct pathways to determining diabetes status and
may result in observations of individuals at different stages of
the condition at the time of diagnosis. Third, prescription data
in the CPRD only indicate when a prescription was issued but
not whether the medication was dispensed or taken as recom-
mended. Fourth, there was a large proportion of missing data
for cardiovascular risk factors in people without diabetes. We
addressed this through multiple imputation with the imputa-
tion model including an extensive range of patient character-
istics and auxiliary variables; importantly, we noted no clini-
cally meaningful differences in measurements of biological
variables when comparing those with and without any missing
data (ESM Tables 2–4). We acknowledge that missing data
may have occurred preferentially in people with normal or
close to normal risk factors (i.e. missing not at random), possi-
bly leading to bias in the magnitude of the association and an
underestimation of the differentials in risk factor levels. Fifth,
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people without type 2 diabetes and attending primary care for
cardiovascular risk factor assessment are likely to have abnor-
mal cardiovascular risk factors or be at risk of diabetes or
CVD. Therefore, measured differences between those with
and without diabetes are potentially underestimated when
compared with a healthier non-diabetic control group. Sixth,
due to the availability of clinical data, we allowed for the
baseline risk factors to be defined from data captured up to
12 months after the index date. This reduced the proportion of
missing data in people without diabetes who may not have
measures frequently recorded. The majority of people diag-
nosed with diabetes will have had information recorded either
on or close to this date. However, a small proportion of indi-
viduals with diabetes would have risk factors recorded only
after clinical intervention. Such intervention would be expect-
ed to improve but not normalise abnormal risk factors.
Therefore, the observed risk factor differences compared with
control counterparts may be somewhat underestimated by our
analysis. Seventh, linkage with hospital data is only available
for people attending English general practices; therefore,
generalisation of our findings to other healthcare systems,
other countries and other ethnic groups at high risk of diabetes
may be limited. However, we would anticipate broadly similar
findings. Finally, we recognise that less frequent screening
means diabetes is being diagnosed later in the course of
disease in younger people. Notably, this cannot explain BMI
differentials by sex (men had higher HbA1c levels but lower
weight differences than women) or by ethnicity (HbA1c levels
were higher or the same but weight differences were far small-
er). It is also unlikely to explain the substantial weight differ-
entials seen across the life course.
Targeted screening and active modification of weight in men
and South Asian and black people, who may be at risk of devel-
oping type 2 diabetes at lower BMI values, may be warranted to
prevent the development of type 2 diabetes. Active intervention
to reduce cardiovascular risk factors other than weight is justified
in all people with type 2 diabetes and those at high risk for
diabetes but these data argue for particular focus in younger
people, where perhaps more aggressive risk factor management
may be needed despite lower mean blood pressures and lower
ten year CVD risks, but high lifetime risks. Further clinical trials
are required to assess the degree of weight reduction required to
achieve diabetes remission by age and ethnicity.
In conclusion, we have provided perhaps the most compre-
hensive assessment of age-, sex- and ethnicity-based differ-
ences in established CVD risk factors at the diagnosis of type
2 diabetes in a high-income country. The findings may help
explain why younger people are more likely to lose additional
life-years when they develop diabetes and also perhaps the
contrast between outcomes in white people and other ethnic-
ities. Clinically, given that men and people from minority
ethnic groups tend to develop diabetes at far lower BMI
values, better targeting of these populations to prevent overt
type 2 diabetes is warranted. However, in all ethnic groups,
risk factor differences, as compared with people without
diabetes, are worse at younger ages suggesting a much greater
need to improve diabetes care in younger people, regardless of
their sex or ethnicity. The high prevalence of abnormal CVD
risk factors in younger people developing diabetes suggests
that there may be value in performing trials in these individ-
uals evaluating the impact of more aggressive lifestyle and/or
pharmacotherapy to promote weight loss and CVD risk
reduction.
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